Browse by Series:

FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year

Gina Columbus
Published: Thursday, Feb 09, 2017



Gina Columbus reports on an FDA approval and 2 priority reviews in bladder cancer, highlights from the 2017 European Cancer Congress, a European approval in lung cancer, and ASCO announces its Cancer Advance of the Year.
Slider Left
Slider Right


Gina Columbus reports on an FDA approval and 2 priority reviews in bladder cancer, highlights from the 2017 European Cancer Congress, a European approval in lung cancer, and ASCO announces its Cancer Advance of the Year.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x